Breaking News Instant updates and real-time market news.

LGND

Ligand

$98.96

-2.8 (-2.75%)

04:55
09/18/19
09/18
04:55
09/18/19
04:55

Ligand management to meet with Craig-Hallum

Meetings to be held in Los Angeles on September 17 and in Salt Lake City on September 18 hosted by Craig-Hallum.

  • 18

    Sep

  • 20

    Sep

  • 08

    Oct

  • 13

    Nov

LGND Ligand
$98.96

-2.8 (-2.75%)

05/03/19
SPHN
05/03/19
NO CHANGE
Target $158
SPHN
Overweight
Ligand news about RVT-1502 has no near-term impact, says Stephens
Stephens analyst Drew Jones noted that Ligand traded lower in the after-hours session despite better than expected quarterly results and a guidance affirmation, which he attributes to the disclosure that Metavant won't be launching its proof-of-concept trial for RVT-1502 in 2019 as expected. However, given that 2019 guidance was reiterated, Jones said nothing from this program had been factored in the company's view. While RVT-1502 is one of the assets with the greatest long-term potential for Ligand, the news from last night has no near-term impact, said Jones, who keeps an Overweight rating and $158 price target on the stock.
06/11/19
LEHM
06/11/19
INITIATION
Target $131
LEHM
Equal Weight
Ligand initiated with an Equal Weight at Barclays
Barclays analyst Balaji Prasad started Ligand Pharmaceuticals with an Equal Weight rating and $131 price target. The analyst launched coverage of 20 U.S. Specialty Pharmaceuticals with a Neutral industry view. He placed importance on cash flows and companies' ability to manage leverage and improve balance sheets.
07/10/19
HCWC
07/10/19
NO CHANGE
Target $214
HCWC
Buy
Ligand data should generate another commercial partnership, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis notes that Ligand announced the anticipated top-line results from the Phase 1 trial of CE-Iohexol, with the study meeting the primary endpoint. The analyst currently does not include CE-Iohexol in our projections, and believes it represents important long-term upside to Ligand's royalty streams. Pantginis would look to reassess its inclusion following a potential partnership and associated terms. Further, he believes that since Ligand has the financial strength, it should progress the drug even further, to likely leverage more favorable terms ahead of any commercial arrangement. The analyst has a Buy rating and $214 price target on the shares.
07/30/19
HCWC
07/30/19
NO CHANGE
Target $214
HCWC
Buy
Ligand shares weak on RVT-1502 update, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis attributes the post-earnings selloff today in shares of Ligand Pharmaceuticals to the company's update on RVT-1502. As part of its quarterly update this morning, Ligand indicated its belief that development of RVT-1502 with partner Metavant in the U.S. is highly unlikely to occur for diabetes, Pantginis tells investors in a research note. The analyst believes this clarity is responsible for today's share weakness but he points out that he's already incorporated this news into his valuation. On May 3 Pantginis removed the asset from his valuation, which lowered his price target for Ligand to the current $214. However, the company's growing OmniAb "juggernaut" continues to not be valued, and is a "company and franchise unto itself," says the analyst. He reiterates a Buy rating on Ligand Pharmaceuticals.

TODAY'S FREE FLY STORIES

SAP

SAP

$129.13

0.55 (0.43%)

05:41
10/21/19
10/21
05:41
10/21/19
05:41
Earnings
SAP continues to expect FY19 revenue to 'increase strongly' »

Backs FY19 non-IFRS cloud…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 19

    Nov

PBF

PBF Energy

$29.29

0.64 (2.23%)

05:39
10/21/19
10/21
05:39
10/21/19
05:39
Upgrade
PBF Energy rating change  »

PBF Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

SAP

SAP

$129.13

0.55 (0.43%)

05:38
10/21/19
10/21
05:38
10/21/19
05:38
Earnings
SAP reports Q3 non-IFRS EPS EUR 1.30 vs. EUR 1.14 last year »

Reports Q3 revenue EUR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 19

    Nov

DANOY

Danone

$0.00

(0.00%)

05:32
10/21/19
10/21
05:32
10/21/19
05:32
Downgrade
Danone rating change  »

Danone downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

JBAXY

Julius Baer

$0.00

(0.00%)

05:30
10/21/19
10/21
05:30
10/21/19
05:30
Downgrade
Julius Baer rating change  »

Julius Baer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHR

Danaher

$138.08

0.31 (0.23%)

05:28
10/21/19
10/21
05:28
10/21/19
05:28
Hot Stocks
Danaher to sell certain businesses to Sartorius AG for $750M »

Danaher announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 07

    Nov

SAP

SAP

$129.13

0.55 (0.43%)

, MSFT

Microsoft

$137.34

-2.34 (-1.68%)

05:26
10/21/19
10/21
05:26
10/21/19
05:26
Hot Stocks
SAP enters go-to-market partnership with Microsoft »

SAP (SAP) and Microsoft…

SAP

SAP

$129.13

0.55 (0.43%)

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 19

    Nov

  • 21

    Nov

ALSMY

Alstom

$0.00

(0.00%)

05:26
10/21/19
10/21
05:26
10/21/19
05:26
Downgrade
Alstom rating change  »

Alstom downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DANOY

Danone

$0.00

(0.00%)

05:25
10/21/19
10/21
05:25
10/21/19
05:25
Downgrade
Danone rating change  »

Danone downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HON

Honeywell

$165.61

-1.87 (-1.12%)

05:24
10/21/19
10/21
05:24
10/21/19
05:24
Hot Stocks
Honeywell sees 7,600 new business jet deliveries over next decade »

The business jet industry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$344.09

-25.04 (-6.78%)

05:23
10/21/19
10/21
05:23
10/21/19
05:23
Downgrade
Boeing rating change  »

Boeing downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

IRT

Independence Realty Trust

$15.03

(0.00%)

05:22
10/21/19
10/21
05:22
10/21/19
05:22
Downgrade
Independence Realty Trust rating change  »

Independence Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

RHHBY

Roche

$0.00

(0.00%)

05:21
10/21/19
10/21
05:21
10/21/19
05:21
Hot Stocks
Genentech says Phase III IMbrave150 study met co-primary endpoints »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

  • 06

    Nov

  • 08

    Nov

  • 11

    Nov

  • 12

    Nov

  • 07

    Dec

PINS

Pinterest

$25.30

-0.7 (-2.69%)

05:21
10/21/19
10/21
05:21
10/21/19
05:21
Upgrade
Pinterest rating change  »

Pinterest upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 19

    Nov

COMM

CommScope

$11.56

-0.06 (-0.52%)

05:20
10/21/19
10/21
05:20
10/21/19
05:20
Upgrade
CommScope rating change  »

CommScope upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

  • 09

    Dec

MFGP

Micro Focus

$15.13

0.56 (3.84%)

, OTEX

OpenText

$39.30

-1.545 (-3.78%)

05:18
10/21/19
10/21
05:18
10/21/19
05:18
Recommendations
Micro Focus, OpenText analyst commentary  »

Micro Focus could attract…

MFGP

Micro Focus

$15.13

0.56 (3.84%)

OTEX

OpenText

$39.30

-1.545 (-3.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 19

    Nov

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

, CRM

Salesforce

$144.18

-1.995 (-1.36%)

05:15
10/21/19
10/21
05:15
10/21/19
05:15
Recommendations
Microsoft, Salesforce, Intuit, SailPoint, Zuora, Varonis analyst commentary  »

High growth software…

MSFT

Microsoft

$137.34

-2.34 (-1.68%)

CRM

Salesforce

$144.18

-1.995 (-1.36%)

INTU

Intuit

$262.54

-4.03 (-1.51%)

SAIL

SailPoint

$18.32

-0.34 (-1.82%)

ZUO

Zuora

$13.63

-0.5 (-3.54%)

VRNS

Varonis

$62.36

-1.56 (-2.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 19

    Nov

  • 21

    Nov

  • 16

    Dec

XLRN

Acceleron

$42.16

-1.02 (-2.36%)

05:09
10/21/19
10/21
05:09
10/21/19
05:09
Recommendations
Acceleron analyst commentary  »

Piper sees near-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 07

    Dec

  • 04

    Apr

TLSNF

Telia

$0.00

(0.00%)

05:04
10/21/19
10/21
05:04
10/21/19
05:04
Downgrade
Telia rating change  »

Telia downgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALRM

Alarm.com

$47.23

-0.5 (-1.05%)

05:01
10/21/19
10/21
05:01
10/21/19
05:01
Upgrade
Alarm.com rating change  »

Alarm.com upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 13

    Nov

  • 09

    Dec

SWAV

ShockWave Medical

$32.30

-0.29 (-0.89%)

04:59
10/21/19
10/21
04:59
10/21/19
04:59
Initiation
ShockWave Medical initiated  »

ShockWave Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

APLS

Apellis

$27.78

-0.03 (-0.11%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Apellis participates in a conference call with JPMorgan »

SMid Biotechnology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Dec

FPRX

Five Prime

$3.98

-0.11 (-2.69%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Five Prime management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

ADAP

Adaptimmune

$0.96

-0.035 (-3.54%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Adaptimmune management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

ALDR

Alder Biopharmaceuticals

$18.92

0.02 (0.11%)

04:55
10/21/19
10/21
04:55
10/21/19
04:55
Conference/Events
Alder Biopharmaceuticals management to meet with Mizuho »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 21

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.